Report for: Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial

Title	Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial
Published in	Trials, June 2019
DOI	10.1186/s13063-019-3321-8
Pubmed ID	31171016
Authors	Eleonora Scaioli, Andrea Belluzzi, Luigi Ricciardiello, Daniele Del Rio, Enrica Rotondo, Pedro Mena, Eleonora Derlindati, Francesca Danesi

X Demographics

The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.

Type	Count	As %
Members of the public	10	71%
Scientists	3	21%
Practitioners (doctors, other healthcare professionals)	1	7%

Mendeley readers

The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	85	100%

Readers by professional status	Count	As %
Student > Bachelor	14	16%
Researcher	10	12%
Student > Master	8	9%
Student > Ph. D. Student	6	7%
Student > Postgraduate	4	5%
Other	12	14%
Unknown	31	36%

Readers by discipline	Count	As %
Medicine and Dentistry	18	21%
Agricultural and Biological Sciences	8	9%
Nursing and Health Professions	7	8%
Biochemistry, Genetics and Molecular Biology	3	4%
Pharmacology, Toxicology and Pharmaceutical Science	3	4%
Other	13	15%
Unknown	33	39%

Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial